sST2 dynamics significantly enhance CAP risk stratification. The discharge-phase biomarker model outperforms conventional scores,a model using D-dimer, procalcitonin, and lymphocyte percentage is a practical alternative. Integrating recovery-phase biomarkers into discharge planning offers a precision medicine strategy to optimize post-discharge management and reduce adverse outcomes.
Li et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: